JP2001131073A5 - - Google Patents

Download PDF

Info

Publication number
JP2001131073A5
JP2001131073A5 JP1999318857A JP31885799A JP2001131073A5 JP 2001131073 A5 JP2001131073 A5 JP 2001131073A5 JP 1999318857 A JP1999318857 A JP 1999318857A JP 31885799 A JP31885799 A JP 31885799A JP 2001131073 A5 JP2001131073 A5 JP 2001131073A5
Authority
JP
Japan
Prior art keywords
salt
diphosphonic acid
hydroxyethylidene
dysesthesia
dichloromethylene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
JP1999318857A
Other languages
English (en)
Japanese (ja)
Other versions
JP2001131073A (ja
Filing date
Publication date
Application filed filed Critical
Priority to JP31885799A priority Critical patent/JP2001131073A/ja
Priority claimed from JP31885799A external-priority patent/JP2001131073A/ja
Publication of JP2001131073A publication Critical patent/JP2001131073A/ja
Publication of JP2001131073A5 publication Critical patent/JP2001131073A5/ja
Abandoned legal-status Critical Current

Links

JP31885799A 1999-11-09 1999-11-09 疼痛治療剤 Abandoned JP2001131073A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP31885799A JP2001131073A (ja) 1999-11-09 1999-11-09 疼痛治療剤

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP31885799A JP2001131073A (ja) 1999-11-09 1999-11-09 疼痛治療剤

Publications (2)

Publication Number Publication Date
JP2001131073A JP2001131073A (ja) 2001-05-15
JP2001131073A5 true JP2001131073A5 (https=) 2006-12-21

Family

ID=18103737

Family Applications (1)

Application Number Title Priority Date Filing Date
JP31885799A Abandoned JP2001131073A (ja) 1999-11-09 1999-11-09 疼痛治療剤

Country Status (1)

Country Link
JP (1) JP2001131073A (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017126700A1 (ja) * 2016-01-20 2017-07-27 芳則 森山 小胞型ヌクレオチドトランスポーター活性阻害剤
JP2019014684A (ja) * 2017-07-07 2019-01-31 国立大学法人大阪大学 真菌感染における宿主応答抑制剤

Similar Documents

Publication Publication Date Title
CA2326517A1 (en) New galenic preparations of meloxicam for oral administration
CA2389235A1 (en) Controlled release hydrocodone formulations
HUP0004383A2 (hu) Hatóanyagként klodronátot és vivőanyagként szilíciumozott mikrokristályos cellulózt tartalmazó gyógyszerészeti készítmény
CA2386690A1 (en) Pharmaceutical tramadol salts
DE69520768D1 (de) Pharmazeutische Zubereitungen, die Fluoxetin enthalten
HUP0100437A2 (hu) Szabályzott felszabadulású gyógyszerkészítmény tolterodin adagolására
CA2601289A1 (en) Once-a-day oxycodone formulations
LU90956I2 (fr) Metvix principe actif méthylaminolevulinique sous forme d'un selde préférence l'hyhrochlorure méthylaminolevulinique
MY125662A (en) Pharmaceutical formulations containing darifenacin
AU2003225617A1 (en) Thiadiazolylpiperazine derivatives useful for treating or preventing pain
NZ514129A (en) Tolperison-containing, pharmaceutical preparation for oral administration
JP2002524415A5 (https=)
IL158668A0 (en) Deuterated 3-piperidinopropiophenone and medicaments containing said compounds
CA2377174A1 (en) Oral administration forms for administering a fixed tramadol and diclofenac combination
JP2004506682A5 (https=)
CA2326339A1 (en) Use of dexmedetomidine for icu sedation
RU2002100058A (ru) Кристаллические производные 1-метилкарбапенема
JP2000159790A5 (https=)
CA2389032A1 (en) Preventive or therapeutic agents for inflammatory diseases of intestine
JP2002522501A5 (https=)
JP2002523437A5 (https=)
WO2001089494A3 (en) Use of zolendronate for the manufacture of a medicament for the treatment of bone metabolism diseases
WO2004050025A3 (en) Combination of ibuprofen and oxycodone for acute pain relief
RU2001118854A (ru) Оптически активное производное пиридил-4н-1,2,4-оксадиазина и его применение при лечении сосудистых заболеваний
AU2173101A (en) Use of carboxy compounds such as 2(4-acetoxyphenyl)-2-chloro-N-methyl-ethylammonium chloride as anti-inflammatory agents